Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/15726
|
| Title: | BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir |
| Authors: | Tang, WF;Chang, YH;Lin, CC;Jheng, JR;Hsieh, CF;Chin, YF;Chang, TY;Lee, JC;Liang, PH;Lin, CY;Lin, GH;Cai, JY;Chen, YL;Chen, YS;Tsai, SK;Liu, PC;Yang, CM;Shadbahr, T;Tang, J;Hsu, YL;Huang, CH;Wang, LY;Chen, CC;Kau, JH;Hung, YJ;Lee, HY;Wang, WC;Tsai, HP;Horng, JT |
| Contributors: | Institute of Biotechnology and Pharmaceutical Research |
| Abstract: | Viral RNA-dependent RNA polymerase (RdRp), a highly conserved molecule in RNA viruses, has recently emerged as a promising drug target for broad-acting inhibitors. Through a Vero E6-based anti-cytopathic effect assay, we found that BPR3P0128, which incorporates a quinoline core similar to hydroxychloroquine, outperformed the adenosine analog remdesivir in inhibiting RdRp activity (EC50 = 0.66 mu M and 3 mu M, respectively). BPR3P0128 demonstrated broad-spectrum activity against various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern. When introduced after viral adsorption, BPR3P0128 significantly decreased SARS-CoV-2 replication; however, it did not affect the early entry stage, as evidenced by a time-of-drug-addition assay. This suggests that BPR3P0128's primary action takes place during viral replication. We also found that BPR3P0128 effectively reduced the expression of proinflammatory cytokines in human lung epithelial Calu-3 cells infected with SARS-CoV-2. Molecular docking analysis showed that BPR3P0128 targets the RdRp channel, inhibiting substrate entry, which implies it operates differently-but complementary-with remdesivir. Utilizing an optimized cell-based minigenome RdRp reporter assay, we confirmed that BPR3P0128 exhibited potent inhibitory activity. However, an enzyme-based RdRp assay employing purified recombinant nsp12/nsp7/nsp8 failed to corroborate this inhibitory activity. This suggests that BPR3P0128 may inhibit activity by targeting host-related RdRp-associated factors. Moreover, we discovered that a combination of BPR3P0128 and remdesivir had a synergistic effect-a result likely due to both drugs interacting with separate domains of the RdRp. This novel synergy between the two drugs reinforces the potential clinical value of the BPR3P0128-remdesivir combination in combating various SARS-CoV-2 variants of concern. |
| Date: | 2024-04 |
| Relation: | Antimicrobial Agents and Chemotherapy. 2024 Apr 3;68(4):Article number e0095623 |
| Link to: | http://dx.doi.org/10.1128/aac.00956-23 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85189762889 |
| Appears in Collections: | [王文傑] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001179421200001.pdf | | 9104Kb | Adobe PDF | 106 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
